Scientists supercharge Patient's own cells to attack breast cancer
NCT ID NCT06251544
Summary
This early-stage study is testing a new type of cell therapy called HTR2 T cells for people with advanced HER2-positive breast cancer that has spread and stopped responding to standard treatments. Doctors take a patient's own immune cells, genetically modify them in a lab to better recognize and attack breast cancer cells, and then infuse them back into the patient. The main goals are to find a safe dose, see how long the cells last, and check if they can shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.